Preprint Title	Revisiting the bromination of 3β-hydroxycholest-5-ene with CBr$_4$/PPh$_3$ and the subsequent azidolysis of the resulting bromide, disparity in stereochemical behavior
Authors	Christian Schumacher, Jas S. Ward, Kari Rissanen, Carsten Bolm and Mohamed R. E. S. Aly
Publication Date	23 Nov 2022
Article Type	Full Research Paper
Supporting Information File 1	2 Checkcif Report.pdf; 72.6 KB
Supporting Information File 2	2.cif; 683.9 KB
Supporting Information File 3	3 Checkcif Report.pdf; 86.6 KB
Supporting Information File 4	3.cif; 1.8 MB
Supporting Information File 5	Aly.BJOC.SI_220919 - Modified - again - 2.docx; 4.3 MB
ORCID® iDs	Christian Schumacher - https://orcid.org/0000-0003-3056-554X; Jas S. Ward - https://orcid.org/0000-0001-9089-9643; Carsten Bolm - https://orcid.org/0000-0001-9415-9917; Mohamed R. E. S. Aly - https://orcid.org/0000-0002-0113-9392

Revisiting the bromination of 3β-hydroxycholest-5-ene with CBr$_4$/PPh$_3$ and the subsequent azidolysis of the resulting bromide, disparity in stereochemical behavior

Christian Schumacher[1], Jas S. Ward[2], Kari Rissanen[2], Carsten Bolm[1], and Mohamed Ramadan El Sayed Aly[3]*

[1]Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany; [2]University of Jyvaskyla, Department of Chemistry, P.O. Box 35, 40014 Jyväskylä, Finland; [3]Chemistry Department, Faculty of Science, Port Said University, 42522-Port Said, Egypt.

Email:

carsten.bolm@oc.rwth-aachen.de;   kari.t.rissanen@jyu.fi;   mrea34@hotmail.com

(mohamed_ramadan@sci.psu.edu.eg)

*   Corresponding author

Abstract

Cholesterol reacts under Appel conditions (CBr$_4$/PPh$_3$) to give 3,5-cholestadiene (elimination) and 3β-bromocholest-5-ene (substitution with retention of configuration). Thus, the bromination of cholesterol deviates from the stereochemistry of the standard Appel mechanism due to participation of the Δ^5 π–electrons. In contrast, the subsequent azidolysis (NaN$_3$/DMF) of 3β-bromocholest-5-ene proceeds predominantly by Walden inversion (S$_N$2) affording 3α-azidocholest-5-ene. The structures of all relevant products were revealed by X-ray single crystal structure analyses, and the NMR data are in agreement to the reported ones. In light of these findings, we herein correct the previous stereochemical assignments reported by one of us in the *Beilstein J. Org. Chem.* **2015**, *11*, 1922–1932 and the *Monatsh. Chem.* **2018**, *149*, 505–517.

Introduction

3*β*-Hydroxycholest-5-ene (cholesterol) is a structural and physiologic amphipathic steroid in human and animals as well. Cholesterol is an essential component of the plasma membrane, where it acts as fluidity buffer, permeability switch, and consequently in cell signaling pathways. Physiologically, cholesterol is the substrate for the biosynthesis of steroidal hormones, vitamin D and bile acids [1,2].

Although cholesterol can adopt 256 stereoisomeric structures, biological significances were only reported for the natural compound (*nat*-cholesterol, **1**) and its enantiomer (*ent*-cholesterol, *ent*-1) (Figure 1) [3]. While **1** and *ent*-**1** are characterized by hydroxyl groups in *β*-position at C3, epicholesterol (*epi*-**1**) has an *α*-OH at C3.

3b-hydroxycholest-5-ene (**1**)
nat-cholesterol

ent-cholesterol (*ent*-**1**)

3a-hydroxycholest-5-ene (*epi*-**1**)
(epicholesterol)

Figure 1. Chemical structure of three isomeric cholesterols.

Diets of animal sources like red meat, liver, milk, and butter provide the body with its daily needs of cholesterol. In addition, hepatocyctes synthesize cholesterol through the mevalonate pathway. Dietary cholesterol is absorbed into the blood stream through a specific membrane bound protein named Niemann-Pick C1-Like 1 (NPC1L1) on the gastrointestinal tract epithelial

cells as well as in hepatocytes. As hydrophobic molecule, it circulates in the blood stream engulfed in carrier lipoproteins of two types, high density lipoproteins (HDL) or good proteins and low-density lipoproteins (LDL) or bad proteins [4,5].

People with a total blood cholesterol over 125−200 mg/dL are considered hypercholeserimic. They are under high risk of cholelithiasis (formation of gallstones), atherosclerosis, heart attack, stroke, peripheral artery disease, and cancer [4,5] Synergistic cholesterol lowering medications are inhibitors of cholesterol absorption (ezetimibe) and cholesterol biosynthesis (statins). However, the side effects of these drugs are controversial. Therefore, synthetic cholesterol derivatives came into focus for recent applications in chemical biology and material science [6]. The advances have been summarized in comprehensive reviews [7,8].

In previous studies, one of us (M. R. E. A.) felt intrigued by the potential of chemical hybridization of cholesterol through simple connections of pharmacophores including sugars, chalcones, quinolone, theophylline, and ferrocene using Click chemistry [9−11]. Following this strategy, cholesterol was propargylated, clicked with azido quinoline, and then functionalized with glucose as part of random designs to discover new antimicrobial and cytotoxic candidates. From these studies, hybride conjugates **I** [9] and **II** [10] were identified to display an excellent preliminary antibacterial impact, and congener **III** [10] showed a good cytotoxic effect against the prostate cancer cell line PC-3 (Figure 2). When the spacer of **I** was increased from C_6 to C_{11}, the antimicrobial potential dramatically decreased [11].

Figure 2. Selected previously described cholesterol derivatives with interesting antibacterial and cytotoxic activities [10,11]. The current results correct the structure of cholesterols **II** and **III** to be in the α- and not, as reported before and shown in this Figure, in the β-configuration.

In order to extend the compound platform, the synthesis of 3-azidocholest-5-ene was addressed [10]. Starting from natural cholesterol, a double inversion of the stereogenic centre at C3 through an Appel type two step conversion of cholesterol into the 3-azido derivative via the corresponding bromide was assumed. Thus, the expected product was 3β-azidocholest-5-ene [12]. Lacking crystallographic evidence, the synthetic chemistry was expanded to click conjugates such as **II** and **III**, and the data was reported [10,11].

Recently, those studies were revisited, and we now obtained single crystals which allowed to unequivocally establishing the relative configurations of the products by X-ray crystallography. Accordingly, the stereochemistry at C3 of the bromo-, azido- and triazolocholesterols was incorrectly assigned, and we now wish to correct the previous reported structures.

Results and discussion

3β-Hydroxy-Δ^5-steroids, for instance, cholesterol, pregnenolone, and their derivatives which possess a potential leaving group at the 3β-position, have a unique feature in their chemical reactions. In these steroids, the breaking of the C3−X bond is facilitated by the formation of a cationic strained cyclopropane intermediate, which is formed by translocation of the C5−π bond electrons to the homoallylic carbon atom at C3 [13] In this way, substitutions at the stereogenic homoallylic carbon atom can proceed with retention of configuration. Concurrently, a so-called *i*-steroid rearrangement leads, for instance, to 6β-azido-3α,5-cyclo-5α-cholestane by 6β–face attack of the steroidal substrate by the nucleophile [14].

In similar work, Peterson and co-workers reported several examples of such stereoretentive conversions of cholesterol, which provided the corresponding 3β-halo- and 3β-azido-5-cholesterenes in high yields [13]. The cholesterol mesylate was the most effective intermediate, and the nucleophiles were trimethylsilyl-based. $TiCl_4$ and $BF_3.OEt_2$ served as activators. No reaction was observed with the 3α-mesyl analog and the cholestane congener. The 3β-azido derivative could also be obtained from 6β-azido-3α,5-cyclo-5α-cholestane [15] by treatment with a mixture of $TMSN_3$ and $BF_3.OEt_2$. All of those results confirmed the involvement of regio- and stereospecific *i*-steroid and retro-*i*-steroid rearrangements. Later, tetrabutylammonium halides were used as cost effective and stable alternatives of TMS–based reagents [16]. Another nice application of this chemistry was recently reported by Oestereich and co-workers, who converted

3β-hydroxypregn-5-en-20-one into the corresponding 3-bromo derivative, which also occurred with retention of configuration at C3 [17].

In 2008, a direct dehydroxyazidation of cholesterol by treatment of the steroid with a zinc azide-pyridine complex, diisopropyl azodicarboxylate (DIAD), and PPh₃ was described [18]. This Mitsunobu-like reaction occurred with complete inversion at C–3 to afforded 3α-azidocholest-5-ene in high yield. The same product was recently obtained by direct dehydroxyazidation of cholesterol upon treatment with *N*-acetyl azidobenziodazolone (ABZ) and PPh₃ in THF [19].

While synthesizing new potential biologically active probes with cholesterol scaffolds in the Port Said laboratories, particularly from 3-azidocholest-5-ene, we started wondering about the previously reported structural and stereochemical assignments of the steroid derivatives. After repeating the C–OH to bromide exchange of cholesterol **1** under Appel conditions, we now found two products. Their polarities were so similar that they merged during color development on the hot TLC plate. Finally, the two compounds could be separated by flash chromatography on silica gel of different mesh numbers. Single crystals of both were obtained by slow evaporation from diethyl ether.

The less polar, minor material gave ice-white needles, and an X-ray single crystal structure determination revealed the product to be cholesta-3,5-diene **2** (Figure 3).


cholesterol (**1**)   cholesta-3,5-diene (**2**)

Figure 3. Top: cholesterol **1** and the less polar product from the Appel reaction, cholesta-3,5-diene **2**; bottom: the X-ray structure of **2** with thermal displacement parameter at 50% probability level.

The ^{1}H NMR spectrum of diene **2** coincided with the previously published spectrum of 3α-bromocholest-5-ene [10], which was erroneously assigned after isolation from a mixture-containing column fraction. Now, the ^{1}H NMR data of **2** are in full agreement with those reported by others [20–22].

The major, slightly more polar product of the Appel reaction was 3β-bromocholest-5-ene **3** (Figure 4). It crystallized as colorless plates, and the structural and stereochemical assignment of **3** was unequivocally confirmed by X-ray crystal structure determination. Previously, that product was erroneously reported to have the α-configuration at C3 [10]. Now, the NMR chemical shift data of **3** are in full agreement with those reported earlier [13].

3b-bromocholest-5-ene (**3**)

Figure 4. Top: the more polar product from the Appel reaction 3-*β*-bromocholest-5-ene **3**; bottom: the X-ray structure of **3** with thermal displacement parameter at 50% probability level.

Previously, the reaction of 3-bromocholest-5-ene with NaN$_3$ in DMF at 90–100 °C was reported to give 3*β*-azidocholest-5-ene. Comparing the respective NMR data with the published ones [13] revealed a difference of about 0.6 ppm for the chemical shift of H–3 suggesting a misassignment [23]. This assumption was confirmed by the X-ray structure analysis of single crystals of **4** obtained from Et$_2$O, which showed the product to be 3*α*-azidocholest-5-ene **4** (Figure 5) [18]. Thus, under the aforementioned conditions, 3*β*-bromocholest-5-ene **3** was predominantly converted into 3-*α*-azidocholest-5-ene **4** involving a stereospecific transformation at C3 proceeding with a Walden inversion. (For note, the ^{1}H NMR spectrum of **4** revealed the presence of ca. 15% of the *β*-epimer, which could result from an incomplete stereospecificity of the substitution opening an alternative reaction path.). Also in this case, the NMR data are then in agreement with the previously reported ones [18,19].

3a-azidocholest-5-ene (**4**)

Figure 5. Top: 3-α-azidocholest-5-ene **4** obtained by treatment of **3** with NaN$_3$ in DMF; bottom: The X-ray crystal structure [18] of **4** (**CSD** [24] refcode **HOFFUE**).

In light of these results, the mechanistic interpretation depicted in Scheme 1 can be provided. Under Appel conditions with a combination of CBr$_4$ and PPh$_3$, 3β-hydroxycholest-5-ene **1** leads to two products, cholesta-3,5-diene **2** and 3β-bromocholest-5-ene **3**. Both **2** and **3** result from intermediate **5**, in which the C3 hydroxyl of **1** is activated. Deprotonation of **5** at C2 with bromide as base provides diene **2** as the minor product. Bromide **3** is formed via cyclopropyl cation **6**, which is generated from **5** by loss of triphenylphosphine oxide being supported by involvement of the Δ^5 π–bond electrons from the α-face. Stereospecific reaction of **6** with bromide as nucleophile leads to **3**, in which the halo substituent is located on the β-side of the molecule. Treatment of **3** with NaN$_3$ in DMF at 90–100 °C provides predominantly azide **4** [23]. This reaction has a high stereospecificity as well, proceeding mostly with inversion of configuration at C3 (Walden inversion). Consequently, the newly introduced substituent is located on the α-face of the steroid. Interestingly, this result contrasts the one observed when 3β-

mesylcholest-5-ene is treated with TMSN₃/BF₃·OEt₂ [13]. There, the process proceeds by retention of configuration locating the azido substituent on the *β*-face of the steroid (compound **7**).

Scheme 1. Mechanistic interpretation of the conversion of cholesterol **1** into diene **2**, bromide **3**, and azides **4** and **7.**

Conclusion

For each product **2–4** the stereochemical assignment has now been confirmed by X-ray single crystal structure determination, and the NMR data are in agreement with those of previous reports. Former structural interpretations of **2–4** as well as those of follow-up compounds [10,11] need to be corrected as shown in (Figure 6).

Figure 6. Compound (next to **2–4**) to be corrected in refs. [10] and [11]. The respective bonds are highlighted in red.

Acknowledgements

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

ORCID®

C. Schumacher – https://orcid.org/ 0000-0003-3056-554X

Jas S. Ward – https://orcid.org/ 0000-0001-9089-9643

Kari Rissanen – https://orcid.org/ 0000-0002-7282-8419

Carsten Bolm – https://orcid.org/0000-0001-9415-9917

Mohamed Ramadan El Sayed Aly – https://orcid.org/0000-0002-0113-9392

General information

Cholesterol was purchased from Advent/India, CBr_4 was purchased from Sigma-Aldrich while, NaN_3 and PPh_3 were purchased from Across. Diethyl ether was purchased from Sigma-Aldrich, while petroleum ether (60−80 ℃), acetone were purchased from Oxford chemicals/India and DMF was purchased from Loba/India. All solvents were pure and used without further purification. Dichloromethane was purchased from Al Nasr/Egypt and dried over CaO before distillation. Flash chromatography was carried out on silica gel (Baker, 30–60 µm) (*Type-I* silica gel) and LiChroprep Si 60 (Merck; Ø (15−25 µm) (*Type-II* silica gel). TLC Monitoring tests were carried out using plastic sheets precoated with silica gel 60 F_{245} (layer thickness 0.2 mm) purchased from Merck. Spots were visualized by their fluorescence under UV−lamp (λ = 245 and 365 nm) or staining with iodine vapor or 15 % H_2SO_4 or $KMnO_4$ solution, or $Ce(IV)SO_4$ in H_2SO_4. Melting points were determined on Gallenkamp apparatus UK and are uncorrected. NMR spectra were recorded on Bruker 600 MHz spectrometer, central laboratory, King Abd El Aziz University, Jeddah, Saudi Arabia and Bruker 400 Spectrometer, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. The ^{13}C NMR spectra are proton decoupled. IR−spectra were recorded on ATR−Alpha FT−IR Spectrophotometer 400–4000 cm^{-1}, Taif University, Taif, Saudi Arabia. Mass spectra were recorded on GCMS−QP 1000Ex Shimadzu spectrometers in the microanalysis unit at Cairo University, Cairo, Egypt.

Reaction of 3β-hydroxycholest-5-ene (1) under Appel condition

Cholest-3,5-diene (2) and 3β-bromocholest-5-ene (3)

As described in [10], a mixture of 3β-hydroxycholest-5-ene (**1**, 0.6 g, 1.5 mmol), PPh_3 (0.5 g, 1.9 mmol) in DCM (5.0 mL) was stirred at ambient temperature, while CBr_4 (0.6 g, 1.8 mmol)

was added portionwise and stirring was continued for an hour. The mixture was evaporated *in vacuo* and the residue was subjected to flash chromatography on *Type-I* then *Type-II* silica gel (petroleum ether) to afford compound **2** (50.0 mg, 8.0%) as white sticks after recrystallization from Et$_2$O and compound **3** (0.55 g, 80%) as creamy plates after recrystallization from Et$_2$O.

Compound **2**: R_f = 0.78 (petroleum ether); mp: 92 ºC* (reported mp: 81.5–82.5 ºC) [20]; ^{1}H NMR (600 MHz, CDCl$_3$): δ = 5.70 (d, J = 9.6 Hz, 1H, H–4), 5.38–5.34 (m, 1H, H–3), 5.16 (m, 1H, H–6), 1.96–76 (m, 26H), 0.73 (s, 3H, CH$_3$–19), 0.69 (d, 3H, $J_{20,21}$ = 6.4 Hz, CH$_3$–21), 0.65 (d, J = 1.2 Hz, 3H, CH$_3$–26/CH$_3$–27), 0.63 (d, J = 1.6 Hz, 3H, CH$_3$–26/CH$_3$–27), 0.48 (s, 3H, CH$_3$–18); ^{13}C {^{1}H} NMR (150 MHz, CDCl$_3$): δ 141.5, 129.0, 125.1, 123.2 (C–3, C–4, C–5, C–6), 57.0, 56.1, 48.4, 42.4, 39.8, 39.5, 36.2, 35.8, 35.2, 33.8, 31.78, 31.77, 28.2, 28.0, 24.2, 23.8, 23.0, 22.8, 22.6, 21.0, 18.8, 18.7 (22 Carbons), 12.0 (CH$_3$–18) [25]; C$_{27}$H$_{44}$ (368.34).

*This melting point was incorrectly attributed to 3α-bromocholest-5-ene in reference [10].

Compound **3**: R_f = 0.75 (petroleum ether); mp: 104 ºC (reported mp: 99.5–100.5 ºC) [13]; ^{1}H NMR (400 MHz, CDCl$_3$): δ 5.38 (dd, J = 2.5 Hz, 1H, H–6), 4.00–3.90 (m, 1H, H–3), 2.81–2.73 (m, 1H), 2.63–2.58 (m, 1H), 2.21–2.18 (m, 1H), 2.10–1.97 (m, 4H), 1.91–1.80 (m, 3H), 1.70–1.23 (m, 8H), 1.20–1.08 (m, 9H), 1.06 (s, 3H, CH$_3$–19), 1.04–1.00 (m, 1H), 0.93 (d, $J_{20,21}$ = 6.4 Hz, 3H, CH$_3$–21), 0.90 (d, J = 1.4 Hz, 3H, CH$_3$–26/CH$_3$–27), 0.88 (d, J = 1.4 Hz, 3H, CH$_3$–26/CH$_3$–27), 0.70 (s, 3H, CH$_3$–18); ^{13}C{^{1}H} NMR (100 MHz, CDCl$_3$): δ 141.5 (C–5), 122.3 (C–6), 57.0, 56.1, 52.6, 50.2, 44.3, 42.3, 40.3, 39.8, 39.7, 36.4, 36.2, 35.8, 34.4, 31.8, 31.7, 28.2, 28.0, 24.3 (18 Carbons), 23.8 (C–23), 22.9, 22.6 (C–26, C–27), 20.9 (C–11), 19.3 (C–19), 18.7 (C–21), 11.8 (CH$_3$–18) [26]; EI–MS (70 eV): calcd for C$_{27}$H$_{45}$Br: 448 [M]$^+$; found: 449 (2) [M+H]$^+$, 370 (3), 369 (17), 368 (53).

3α-Azidocholest-5-ene (4)

As described in [10], a mixture of **3** (4.3 g, 9.5 mmol) and NaN_3 (3.0 g, 46.1 mmol) in DMF (25 mL) was stirred at 90−100 ºC for 48 h then diluted with H_2O (25 mL). The mixture was extracted with dichloromethane (3 x 50 mL), dried over Na_2SO_4 and evaporated *in vacuo*. The residue was subjected to flash chromatography (petroleum ether) to afford compound **4** (2.47 g, 63%) as faint creamy sticks upon crystallization from Et_2O. R_f = 0.26 (petroleum ether); mp: 98 ºC [10] (reported mp: 114−115 ºC [18]; IR: υ = 2081 (N_3 *str*) cm^{-1}; ^1H NMR (600 MHz, $CDCl_3$): δ = 5.39 (t, *J* = 2.3, 4.8 Hz, 1H, H−6), 3.87 (t, *J* = 3.0, 6.0 Hz, 1H, H−3), 3.20 (m, 0.15H),* 2.53 (ddd, *J* = 2.4,, 2.4, 15.0 Hz, 1H, H−4a), 2.29 (d, *J* = 8.4 Hz, 0.3H),** 2.18 (ddd, *J* = 2.4, 2.4, 14.4 Hz, 1H, H−4b), 2.03−1.94 (m, 2H), 1.92−1.68 (m, 3H), 1.66−1.22 (m, 6H), 1.19−0.98 (m, 15H), 1.00 (s, 3H, CH_3−19), 0.91 (d, $J_{20,21}$ = 6.6 Hz, 3H, CH_3−21), 0.87 (d, *J* = 2.4 Hz, 3H, CH_3−26/CH_3−27), 0.86 (d, *J* = 2.4 Hz, 3H, CH_3−26/CH_3−27), 0.68 (s, 3H, CH_3−18); $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ = 138.1 (C−5), 123.2 (C−6), 58.3 (C−3), 56.6 (C−14), 56.1 (C−17), 50.1 (C−9), 42.3 (C−13), 39.7 (C−12), 39.5 (C−24), 37.1 (C−10), 36.2 (C−22), 36.1 (C−4), 35.8 (C−20), 33.6 (C−1), 31.82, 31.8 (C−7, C−8), 28.2 (C−16), 28.0 (C−25), 26.1 (C−2), 24.1 (C−15), 23.8 (C−23), 22.8, 22.6 (C−26, C−27), 20.7 (C−11), 19.0 (C−19), 18.7 (C−21), 11.9 (C−18) [27]; EI−MS (70 eV): calcd for $C_{27}H_{45}N_3$: 411 $[M]^+$; found: 412 (2) $[M+H]^+$, 411 (4) $[M]^+$, 393 (2), 383 (49), 368 (78).

* This signal is attributed to the H-3 of (15%) by-product 3β-azidocholest-5-ene; ** denotes to two protons of the 3β-azidocholest-5-ene epimer [13].

References

1. Cerqueira, N. M. F. S. AOliveira, .; E. F.; Gesto, D. A.; Santoa-Martins, D.; Moreira, C.; Moorthy, H. M.; Ramos, M. J.; Fernandes, P. A. *Biochem.* **2016**, *55*, 5483–5506. doi.org/10.1021/acs.biochem.6b00342

2. Levitan, I.; Singh, D. K.; Rosenhouse-Dantsker, A. *Front. Physiol.* **2014**, *5*, 65. https://doi.org/10.3389/fphys.2014.00065

3. Geva, M.; Izhaky, D.; Mickus, D. E.; Rychnovsky, S. D.; Addadi, L.; *ChemBioChem* **2001**, *2*, 265−271. doi.org/10.1002/1439-7633(20010401)2:4<265::AID-CBIC265>3.0.CO;2-V

4. Brown, M. S.; Radhakrishnan, A.; Goldstein, J. L. *Annu. Rev. Biochem.* **2018**, *87*, 783–807. doi: 10.1146/annurev-biochem-062917-011852

5. Groenen, A. G.; Halmos, B.; Tall, A. R.; Westerterp, M. *Crit. Rev. Biochem. Mol. Biol.* **2021,** *56*, 426-439. doi: 10.1080/10409238.2021.1925217. Epub 2021 Jun 28

6. Charaschanya, M.; Aubé, J. *Nat. Commun.* **2018**, *9*, 934. doi.org/10.1038/s41467-018-03248-2

7. Morzycki, J. W. *Steroids* **2014**, *83*, 62–79. doi.org/10.1038/s41467-018-03248-2

8. Albuquerque, H. M. T.; Santos, C. M. M.; Silva, A. M. S. *Molecules* **2019**, *24*, 116. doi.org/10.3390/molecules24010116

9. Aly, M. R. E.; Saad, H. A.; Mohamed, M. A. M. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 2824–2830. DOI: 10.1016/j.bmcl.2015.04.096

10. Aly, M. R. E.; Saad, H. A.; Abdel Hafez, S. H. *Beilstein J. Org. Chem.* **2015**, *11*, 1922–1932. doi.org/10.3762/bjoc.11.208

11. Aly, M. R. E.; El Azab, I. H.; Gobouri, A. A. *Monatsh. Chem.* **2018**, *149,* 505−517. doi.org/10.1007/s00706-017-2093-7

12. Xu, W.; Luo, B.; Li, C.; Yang, J.; Zhou, C. *Adv. Mat. Res.* **2013**, *647*, 499–503. doi:10.4028/www.scientific.net/AMR.647.499

13. Sun, Q.; Cai, S.; Peterson, B. R. *Org. Lett.* **2009**, *11*, 567−570. doi.org/10.1021/ol802343z

14. Shoppee, C. W.; Summers, H. R. *J. Chem. Soc.* **1952**, 3361–3374. doi.org/10.1039/JR520003361

15. Freiberg, L. A. *J. Org. Chem.* **1965**, *30*, 2476–2479. doi.org/10.1021/jo01018a518

16. Xie, Z.; Gong, S.; Sun, Q. *Adv. Mat. Res.* **2014**, *848*, 199−202. doi.org/10.1021/jo01018a518

17. Xue, W.; Shishido, R.; Oestereich, M. *Angew. Chem. Int. Ed.* **2018**, *57*, 12141−12145; *Angew. Chem.* **2018**, *130*, 12318–12322. DOI: 10.1002/anie.201807640

18. Houston, T. A.; Quader, S.; Boyd, S. E.; Jenkins, I. D.; Healy, P. C. *Acta. Cryst.* **2008**, *E64*, o1738. doi: 10.1107/S160053680905421X

19. Yang, X.-G.; Du, F. H.; Li, J.-J.; Zhang, C. *Chem. Eur. J.* **2022**, *28*, e202200272. doi.org/10.1002/chem.202200272

20. Cacchi, S.; Morera, E.; Ortar, G. *Org. Synth.* **1990**, *68*, 138; *Org. Synth.* **1993**, *8*, 126. DOI: 10.15227/orgsyn.068.0138

21. Xiong, Q.; Wilson, W. K.; Pang J. *Lipids* **2007**, *42*, 87–96. doi.org/10.1007/s11745-006-3013-5

22. Derewiaka, D. *Eur. J. Lipid Sci. Technol.* **2019**, *121*, 1800373. doi.org/10.1002/ejlt.201800373

23. A close inspection of the NMR spectra of **4** (see Figs. S14-S21 in the SI) suggests the presence of trace amounts of 3β-azido isomer **7** as revealed by the signals at $\delta = 3.2$ ppm in the ^{1}H NMR spectrum and $\delta = 139.8$ and 122.5 ppm in the ^{13}C{^{1}H} NMR spectrum being in line with the data for H3, C5, and C6, respectively, reported in ref [13].

24. a) Cambridge Structural Database (ConQuest version 2022.2.0), Cambridge Crystallographic Data Centre, Cambridge, United Kingdom, **2022**; b) Groom, C. R.; Bruno, I. J.; Lightfoot, M. P.; Ward, S. C. *Acta Cryst.* **2016**, *B72*, 171–179. doi.org/10.1107/S2052520616003954

25. These NMR values fit with the partial data reported in ref. [20].

26. These NMR values fit with the reported data in ref. [13].

27. These NMR values fit with those of reported data in ref. [18].